News

Zacks Investment Research on MSN5d
Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate
Arcturus Therapeutics Holdings Inc. ARCT announced that the FDA has granted a Fast Track designation to its self-amplifying ...
Arcturus Therapeutics granted fast track designation for ARCT-2304 from FDA
Arcturus Therapeutics (ARCT) announced that the FDA has granted fast track designation for the self-amplifying mRNA vaccine candidate, ...
Arcturus Therapeutics price target lowered to $45 from $71 at Guggenheim
Guggenheim analyst Seamus Fernandez lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $45 from $71 and keeps a Buy rating on ...
Arcturus Gets FDA Fast-Track Designation for Pandemic Influenza A H5N1 Vaccine
Arcturus Therapeutics Holdings has won U.S. Food and Drug Administration fast-track designation for its ARCT-2304 pandemic flu vaccine candidate.
Yahoo Finance1mon
Arcturus Therapeutics Holdings Inc (ARCT) Q4 2024 Earnings Report Preview: What To Look For
Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) is set to release its Q4 2024 earnings on Mar 6, 2025.The consensus estimate for Q4 2024 revenue is $44.65 million, and the earnings are expected ...
Yahoo Finance7d
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1
SAN DIEGO, April 10, 2025--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicine company focused on the development of ...
Business Wire1mon
Arcturus Therapeutics to Present at Leerink’s Global Healthcare Conference 2025
SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of ...